Who is sponsoring NCT03608072?

NCT03608072 is sponsored by Boehringer Ingelheim.

What drugs are being tested in NCT03608072?

Interventions: BI 690517, Placebo.

What is the status of NCT03608072?

NCT03608072 is currently COMPLETED.

Last reviewed 2024-11-25 · How we verify

A Study in Healthy Japanese Men to Test How Different Doses of BI 690517 Are Taken Up in the Body and How Well They Are Tolerated

NCT03608072 PHASE1 COMPLETED

The primary objective of the trial is to investigate the safety and tolerability of BI 690517 in healthy Japanese male subjects following oral administration of multiple rising doses over 14 days. Secondary objective is the exploration of the pharmacokinetic(s) (PK) and pharmacodynamic(s) (PD) of BI 690517 in healthy Japanese male subjects after multiple dosing.

Details

Lead sponsor	Boehringer Ingelheim
Phase	PHASE1
Status	COMPLETED
Enrolment	36
Start date	Mon Aug 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Thu Jan 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Healthy

Interventions

BI 690517
Placebo

Countries

Japan